1199P MAVERIC: Phase II randomized study of everolimus as maintenance therapy for metastatic neuroendocrine neoplasms (mNEN) with pulmonary or gastroenteropancreatic (GEP) origin. Results on behalf of the GOIRC
Annals of Oncology(2023)
摘要
NEN are a group of heterogeneous malignancies that most commonly arise in the GEP tract. Usually > 20% Ki-67 NEN, including both well and poorly differentiated, are treated with chemotherapy (CT) but the schedule and duration is debated and no evidence about a maintenance therapy exists. MAVERIC is a randomized, multicentric, phase II trial. Patients (pts) with well/moderately or poorly differentiated mNEN from GEP or lung primary sites with Ki-67 between 20% and 55% in response after a first -line (1L) CT were randomized with a 2:1 ratio to maintenance therapy with everolimus 10 mg day or to observation until progression or treatment intolerance. Randomization was done using a centralized web-based system. The primary endpoint was progression free survival (PFS) and the secondary endpoints were overall survival (OS) and safety. The study design was formally non-comparative. Of 30 patients enrolled between 2015 and 2022 in 5 centers, 20 were randomized to everolimus and 10 to observation; 29 resulted eligible for the analysis. 52% had a GEP and 48% a pulmonary primary site. The median follow-up was 30.3 mo. Median PFS was longer for the experimental arm (1.8 mo vs. 11.4 mo; p=0.022). Median OS was 38.3 and 38.2 mo for the experimental and control arms, respectively (p=0.43). In the experimental arm, G3 adverse events (AEs) occurred in 55% of pts (most commonly mucositis/stomatitis (27.7%) and neutropenia (27.7%)). No G4 AEs occurred. 65% of pts required a dose reduction and 2 pts discontinued treatment due to AEs. This study may suggest a role for everolimus as a maintenance therapy following 1L CT in selected pts with high-grade GEP or lung NEN with Ki67 between 20% and 55%. Homogeneous prospective studies are warranted to validate this hypothesis.
更多查看译文
关键词
metastatic neuroendocrine neoplasms,everolimus
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要